Literature DB >> 19379121

Recombinant FSH in the treatment of oligozoospermia.

Carlo Foresta1, Riccardo Selice, Alberto Ferlin, Andrea Garolla.   

Abstract

BACKGROUND: FSH plays a crucial role in human reproduction. Treatment with gonadotrophins has been shown to be effective in males affected by hypogonadotrophic hypogonadism. The success of this treatment has brought about the utilization of the same therapy in infertile oligozoospermic subjects, aimed at obtaining increased sperm count. This physiological role in spermatogenesis has induced various attempts to treat idiopathic oligozoospermic men with FSH, often inducing the restoration of normal spermatogenesis and spontaneous pregnancy.
OBJECTIVE: To evaluate clinical efficacy of recombinant FSH in male infertility.
METHODS: Evaluation of pharmacokinetic, pharmacodynamic properties, efficacy and safety of this hormone preparation, on the basis of the data published in literature.
CONCLUSIONS: Recombinant FSH is effective, safe and well tolerated. Treatment with this hormone may represent a valid tool for infertile men. However it should be performed on selected patients utilizing some predictive parameters able to identify a priori responder subjects with high probability.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19379121     DOI: 10.1517/14712590902932673

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  8 in total

Review 1.  Are circulating gonadotropin isoforms naturally occurring biased agonists? Basic and therapeutic implications.

Authors:  Brian J Arey; Francisco J López
Journal:  Rev Endocr Metab Disord       Date:  2011-12       Impact factor: 6.514

2.  Effects of highly purified follicle-stimulating hormone on sperm DNA damage in men with male idiopathic subfertility: a pilot study.

Authors:  S Palomba; A Falbo; S Espinola; M Rocca; S Capasso; F Cappiello; F Zullo
Journal:  J Endocrinol Invest       Date:  2011-05-23       Impact factor: 4.256

3.  Management of male factor infertility: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS) : Endorsing Organization: Italian Society of Embryology, Reproduction, and Research (SIERR).

Authors:  A Ferlin; A E Calogero; C Krausz; F Lombardo; D Paoli; R Rago; C Scarica; M Simoni; C Foresta; V Rochira; E Sbardella; S Francavilla; G Corona
Journal:  J Endocrinol Invest       Date:  2022-01-24       Impact factor: 4.256

Review 4.  Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism.

Authors:  A Lenzi; G Balercia; A Bellastella; A Colao; A Fabbri; C Foresta; M Galdiero; L Gandini; C Krausz; G Lombardi; F Lombardo; M Maggi; A Radicioni; R Selice; A A Sinisi; G Forti
Journal:  J Endocrinol Invest       Date:  2009-12-01       Impact factor: 4.256

5.  Recombinant follitropin alfa/lutropin alfa in fertility treatment.

Authors:  Ahmed Gibreel; Siladitya Bhattacharya
Journal:  Biologics       Date:  2010-02-04

6.  "In vitro" Effect of Different Follicle-Stimulating Hormone Preparations on Sertoli Cells: Toward a Personalized Treatment for Male Infertility.

Authors:  Iva Arato; Giuseppe Grande; Ferran Barrachina; Catia Bellucci; Cinzia Lilli; Meritxell Jodar; Maria Chiara Aglietti; Francesca Mancini; Federica Vincenzoni; Alfredo Pontecorvi; Riccardo Calafiore; Rafael Oliva; Giovanni Luca; Francesca Mancuso; Domenico Milardi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-18       Impact factor: 5.555

Review 7.  Follicle-stimulating Hormone (FSH) Action on Spermatogenesis: A Focus on Physiological and Therapeutic Roles.

Authors:  Daniele Santi; Pascale Crépieux; Eric Reiter; Giorgia Spaggiari; Giulia Brigante; Livio Casarini; Vincenzo Rochira; Manuela Simoni
Journal:  J Clin Med       Date:  2020-04-03       Impact factor: 4.241

Review 8.  FSH for the Treatment of Male Infertility.

Authors:  Livio Casarini; Pascale Crépieux; Eric Reiter; Clara Lazzaretti; Elia Paradiso; Vincenzo Rochira; Giulia Brigante; Daniele Santi; Manuela Simoni
Journal:  Int J Mol Sci       Date:  2020-03-25       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.